Biogen Idec announced that the FDA approves orphan drug Alprolix

Publicado por en 31 Mar, 2014 en Noticias | Sin comentarios

Biogen Idec announced that the FDA approves orphan drug Alprolix

Biogen Idec announced on March 28th that the FDA approves orphan drug Alprolix (coagulation factor IX (recombinant), Fc fusion protein), the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body for use in children and adults.

The approval of Alprolix is the first significant advance in hemophilia B treatment in more than 17 years. The therapy is clinically proven to reduce bleeding episodes with a favorable safety and tolerability profile. It is developed using a process called Fc fusion and is the first hemophilia therapy to demonstrate prolonged circulation in the body, which has been shown in adults and adolescents with hemophilia to extend the time between prophylactic infusions.

 

 

Dejar una Respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies